Bank of America Securities released a research report stating that the target price of Ali Health was lowered from HK$5.1 to HK$4.2, reaffirming the “buy” rating. The bank lowered the company's 2027 revenue and adjusted net profit forecast by 4%, respectively, to a year-on-year increase of 9% to RMB 37.4 billion and a year-on-year decrease of 10% to RMB 2.1 billion, mainly affected by reduced platform subsidies and weak sales in non-pharmaceutical categories.

Bank of America Securities released a research report stating that the target price of Ali Health was lowered from HK$5.1 to HK$4.2, reaffirming the “buy” rating. The bank lowered the company's 2027 revenue and adjusted net profit forecast by 4%, respectively, to a year-on-year increase of 9% to RMB 37.4 billion and a year-on-year decrease of 10% to RMB 2.1 billion, mainly affected by reduced platform subsidies and weak sales in non-pharmaceutical categories.